for their interest in our review of high molecular mass forms of circulating prolactin 2 and for their stimulating comments. Dorizzi et al. 1 question whether a screening programme to detect macroprolactinaemia (hyperprolactinaemia solely due to macroprolactin) is necessary when using a prolactin assay with relatively low crossreactivity with macroprolactin. This question is particularly relevant to the Beckman Access prolactin assay since it has been reported recently that in this assay macroprolactin is the cause in o2% of all samples with elevated total prolactin; 3 but we would emphasize that macroprolactin can cause hyperprolactinaemia in all the widely used assays for prolactin, as reported elsewhere in this volume. 4 Decisions on the introduction of screening tests for macroprolactinaemia should be made in each institution after discussion between the laboratory and clinical sta¡, and the expected frequency of detection of macroprolactin-positive sera, which will depend to a considerable extent on the analytical system in place, will be an important factor to consider.
The clinical consequences and costs of not screening should also be considered. Gibney et al. 5 and Suliman et al. 6 have shown that patients with macroprolactinaemia cannot be distinguished reliably from those with true hyperprolactinaemia on clinical grounds and that before the introduction of a screening programme, macropolactinaemia was a cause of misdiagnosis and mistreatment of patients with hyperprolactinaemia. Long-term, inappropriate treatment with dopamine agonists and pituitary surgery have been reported and the diagnostic confusion caused by macroprolactinaemia also leads to unnecessary further investigation, with many patients undergoing pituitary imaging at considerable cost. 2, 5, 6 In contrast a simple, inexpensive PEG precipitation technique can be applied to most prolactin assays (including the Beckman Access assay 3 ), to detect macroprolactinaemia and provide an estimate of monomeric prolactin. In the experience of one of us (MNF-W) in a District General Hospital serving a population of 350,000, approximately 8% of the 2000 requests for serum prolactin assay received each year are signi¢cantly elevated (4700 mU/L) with the Wallac DELFIA assay and the marginal costs of screening for macroprolactinaemia in these with the PEG precipitation technique are approximately »1500. The number of samples requiring screening would be less when using an assay which reacts less strongly with most forms of macroprolactin. When all the factors are considered, screening for macroprolactinaemia may be justi¢ed on clinical and economic grounds even when hyperprolactinaemia due to macroprolactin is detected infrequently.
Dorizzi et al. 1 suggest that when using a prolactin assay with which hyperprolactinaemia due to macroprolactin occurs relatively infrequently, it may be more e⁄cient to con¢rm that hyperprolactinaemia persists after 30--60 min of a saline infusion before screening for macroprolactinaemia. It is not possible to evaluate this proposal without data comparing how frequently macroprolactin and stress cause hyperprolactinaemia. In our experience, the saline infusion test is not widely used in the UK and it would be most valuable if Dorizzi et al. were able to provide data from their practice. We are aware that some authorities consider that stress has been overemphasized as a cause of hyperprolactinaemia 7 and that the saline infusion test is invasive and inconvenient in that it requires a further appointment for the patient.
Finally, Dorizzi et al. 1 suggest that clinical laboratories indicate the assay used in the reports of all endocrinology assays, and especially of prolactin, to allow clinicians to establish the reliability of the reports but it seems unlikely that clinicians will be su⁄ciently familiar with the characteristics of each assay to make such a judgement.
Behind a clinical request for serum prolactin assay is the question 'are this patient's symptoms due to hyperprolactinamia'? When total serum prolactin is found to be elevated we believe that the only reliable way to answer this question is to provide a measure of the monomeric prolactin that is bioactive in vivo, and this is best done by using techniques such as PEG precipitation to remove high molecular mass forms of prolactin that are not bioactive in vivo. On the basis of current evidence, we concur with Gibney et al. 5 and recommend that the ideal approach is to screen all samples with elevated total serum prolactin for macroprolactinaemia, irrespective of the assay used, and report a measure of monomeric prolactin. 
